<b>Gapping up <br/><br/></b>b]In reaction to strong earnings/guidance:[/b] TIK +10.7%, OHGI +8.5%, BCOM +5.3%, (co's subsid posted earnings update), PLUG +2.2%, YOD +1%<br/><br/><b>M&A news:</b> ERIC +1.6% (Friday rumors of acquisition by Cisco (CSCO); states recent partnership had no discussions of merger)<br/><br/><b>Select metals/mining stocks trading higher: </b>AUY +2.7%, AEM +1.6%, SLW +1.5%, GDX +1%, BHP +0.7%, GLD +0.7%<br/><br/><b>Select oil/gas related names showing strength:</b> RDS.A +1.2%, RIG +1.1%, BP +0.7%, CHK +0.5%, TOT +0.4%<br/><br/><b>Other news: </b>NLST +21.5% (U.S. Federal Court of Appeals upheld the validity of all claims in the reexamination of U.S. Pat. No. 7,532,537 brought by Inphi (IPHI)), NVET +16.8% (reports results of NV-01 pivotal study in dogs; study met primary endpoint), BIOL +13.3% (Jack W. Schuler, ~20% active stake, discloses entry into standstill agreement), ARWR +7.4% (presents data showing robust sustained anti-viral effects with ARC-520 in Hepatitis B), FCEL +7.4% (still checking), GLPG +6.1% (still checking; rebounding pre-mkt following last week's declines), ARRY +5.5% (Array Biopharma and Pierre Fabre announces collaboration to develop and commercialize Array's late-stage novel oncology products, binimetinib and encorafenib), PLX +5.2% (files for $100 mln mixed securities shelf offering; also initiates a Phase III Clinical Trial for PRX-102 to treat Fabry Disease, following a successful end-of-phase II meeting with the FDA), NATH +3.6% ( increases the price range of its previously announced Dutch Auction tender offer), MBT +3.2% (cont strength), SODA +3.1% (CEO purchases 30k ordinary shares on the open market), CGIX +3% (Frigate Ventures discloses 6.5% passive stake in 13G filing), IBN +2.4% (outperformer in the Sensex today), SUNE +1.8% (profiled in Barrons), VIPS +1.7% (pre-mkt rebound after last week's declines)<br/><br/><b>Analyst comments: </b>PRGO +1.8% (upgraded to Buy from Neutral at UBS), BUD +1.8% (upgraded to Outperform at Exane BNP Paribas ), NVDA +1% (upgraded to Buy from Hold at Canaccord Genuity ), ORCL +0.9% (added to Conviction Buy List at Goldman), AV +0.7% (upgraded to Buy at BofA/Merrill)<br/><br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance: </b>DDS -10.3%, ASTI -7.9%, SORL -4.6%, MOBI -4.6%, AUMN -3.1%<br/><br/><b>M&A news: </b>HOT -5.1% (Starwood Hotels to be acquired by Marriott (MAR) for ~$12.2 bln, or roughly $79.88/share in cash/stock), SYT -2.8% (weakness pre-mkt, may be giving back gains from Friday after no new news on M&A talks), MAR -1.2% (see HOT)<br/><br/><b>Select Travel and Leisure related names showing weakness after Paris attacks:</b> CCL -1.9%, EXPE -1.8%, CTRP -1.6%, DAL -1.5%, ALK -1.2%, RCL -0.8%<br/><br/><b>Other news: </b>CLVS -59% (announces that the FDA requested additional clinical data for use in the efficacy analysis for both the 500mg and 625mg BID dose patient groups for rociletinib), KBIO -52.2% (to wind down operations, engages the Brenner Group to lead efforts), HOT -5.3% ( to be acquired by Marriott (MAR) for ~$12.2 bln, or roughly $79.88/share in cash/stock), FIVE -4.8% (downgraded to Hold from Buy at Deutsche Bank), RPTP -4.8% (provides additional results on RP103, re-iterating there was no difference in the response rate between RP103 and placebo), NBG -1.9% (cont weakness), KKR -1.5% (filess for ~2.63 mln share offering of common units by selling unitholders), TI -1% (Telecom Italia receives request from Vivendi (VIVHY) to supplement the agenda of upcoming shareholders meeting; Vivendi planning to appoint four directors)<br/><br/><b>Analyst comments:</b> CNHI -4.7% (downgraded to Underweight from Neutral at JP Morgan ), MNKD -3.7% (downgraded to Neutral at Griffin Securities ), BBY -1.4% (downgraded to Sector Perform at RBC Capital Mkts)<br/><br/>Briefing.com